REGISTERED NUMBER: 00397744 (England and Wales)

Donald G Hayden (Chemists) Limited

Unaudited Financial Statements for the Year Ended 31 January 2025

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

K S Dhanoa

M H Patel

REGISTERED OFFICE:

Hayden House

Bridge Road

Lowestoft

Suffolk

NR32 3LL

REGISTERED NUMBER:

00397744 (England and Wales)

ACCOUNTANTS:

Smailes Goldie

Chartered Accountants

Regent's Court

Princess Street

Hull

East Yorkshire

HU2 8BA

FIXED ASSETS

Intangible assets

4

415,598

195,217

Tangible assets

5

103,126

103,033

Investments

6

280,813

280,813

Investment property

7

208,330

184,256

1,007,867

763,319

CURRENT ASSETS

Stocks

479,832

480,832

Debtors

8

1,838,479

1,899,812

Cash at bank and in hand

505,586

539,766

2,823,897

2,920,410

CREDITORS

Amounts falling due within one year

9

1,105,260

1,197,711

NET CURRENT ASSETS

1,718,637

1,722,699

TOTAL ASSETS LESS CURRENT LIABILITIES

2,726,504

2,486,018

PROVISIONS FOR LIABILITIES

20,925

19,998

NET ASSETS

2,705,579

2,466,020

CAPITAL AND RESERVES

Called up share capital

8,900

8,900

Retained earnings

2,696,679

2,457,120

SHAREHOLDERS' FUNDS

2,705,579

2,466,020

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22 October 2025 and were signed on its behalf by:

K S Dhanoa - Director

1.	STATUTORY INFORMATION

Donald G Hayden (Chemists) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared in accordance with applicable accounting standards including Financial Reporting Standard 102 the Financial Reporting Standard Applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. The financial statements have been prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value

The significant accounting policies applied in the preparation of these financial statements are set out below.

Preparation of consolidated financial statements

The financial statements contain information about Donald G Hayden (Chemists) Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of businesses in 2003, 2012 , 2013 and 2025, is being amortised evenly over its estimated useful life of 20 years. The amortisation policy reflects the period over which future cash flows are expected to be generated from these pharmacies.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Plant, machinery and equipment

15% on a reducing balance basis

Motor vehicles

15% on a reducing balance basis

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Impairment

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

Loans and borrowings

Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.

Leases

Rentals payable and receivable under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 52 (2024 - 67 ) .

4.	INTANGIBLE FIXED ASSETS

Goodwill

£

COST

At 1 February 2024

470,500

Additions

253,467

At 31 January 2025

723,967

AMORTISATION

At 1 February 2024

275,283

Charge for year

33,086

At 31 January 2025

308,369

NET BOOK VALUE

At 31 January 2025

415,598

At 31 January 2024

195,217

5.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 February 2024

818,508

Additions

17,067

At 31 January 2025

835,575

DEPRECIATION

At 1 February 2024

715,475

Charge for year

16,974

At 31 January 2025

732,449

NET BOOK VALUE

At 31 January 2025

103,126

At 31 January 2024

103,033

6.	FIXED ASSET INVESTMENTS

Shares in

group

undertakings

£

COST

At 1 February 2024

and 31 January 2025

280,813

NET BOOK VALUE

At 31 January 2025

280,813

At 31 January 2024

280,813

7.	INVESTMENT PROPERTY

Total

£

FAIR VALUE

At 1 February 2024

184,256

Additions

24,074

At 31 January 2025

208,330

NET BOOK VALUE

At 31 January 2025

208,330

At 31 January 2024

184,256

Investment property was valued on an open market basis on 31st January 2025 by the directors.

8.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

756,034

676,385

Amounts owed by group undertakings

808,338

908,730

Other debtors

274,107

314,697

1,838,479

1,899,812

9.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade creditors

884,692

829,067

Taxation and social security

199,495

355,852

Other creditors

21,073

12,792

1,105,260

1,197,711

10.	OTHER FINANCIAL COMMITMENTS

Total financial commitments which are not included in the balance sheet amount to £1,379,165 (2024 £1,513,327) of which £134,163 (2024 £134,163) falls due for payment within one year.

11.	RELATED PARTY DISCLOSURES

Included in other debtors is an amount of £10,751 (2024: £157,755) due from a director. Interest is charged at the HMRC beneficial loan interest rate and the loan is repayable on demand.

Included in other debtors is an amount of £49,225 (£60,000) in respect of a loan to Kessingland Pharma Ltd, a company under common control. No interest is charged on this loan.